The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Alzheimer disease and aducanumab: adjusting our approach
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Currently, there is no treatment to stop, prevent, or reverse AD, and recent advances with monoclonal antibody therapy targeting plaques, although controversial, might at best only slow progression (Huang and Mucke, 2012; Selkoe, 2019; Sevigny et al., 2016).”
From Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer’s model (2022) · cites this paper as Selkoe, 2019
In the citing paper
“The lack of robust efficacy in trials that utilize therapies directed against amyloid and inflammatory pathways, even when initiated relatively early in the disease (Selkoe, 2019; Imbimbo et al., 2010), suggests that other mechanisms are at play.”
From Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer’s model (2022) · cites this paper as Selkoe, 2019
In the citing paper
“however, thus far, treatments to decrease formation of plaques have shown only minimal or no improvement in disease progression or outcomes (Knopman et al., 2021; Selkoe, 2019).”
From Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer’s model (2022) · cites this paper as Selkoe, 2019
In the citing paper
“Currently, there is no treatment to stop, prevent, or reverse AD, and recent advances with monoclonal antibody therapy targeting plaques, although controversial, might at best only slow progression (Huang and Mucke, 2012; Selkoe, 2019; Sevigny et al., 2016).”
From Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer’s model (2022) · cites this paper as Selkoe, 2019
In the citing paper
“Unfortunately, two phase 3 trials in mild AD were stopped early for futility in March 2019 after interim analysis suggested no change in cognitive decline (Selkoe, 2019).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Selkoe, 2019
Citations
Cites
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059
Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242
Microglial signatures and their role in health and disease
Butovsky, O., & Weiner, H. L. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0057-5 · Cited by 1,046
The A4 Study: Stopping AD Before Symptoms Begin?
Sperling, R. A., Rentz, D. M., Johnson, K. A., Karlawish, J. H., Donohue, M., Salmon, D. P., & Aisen, P. S. S. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007941 · Cited by 778
Preventing Alzheimer’s Disease
Selkoe, D. J. (2012) · Science · doi:10.1126/science.1228541 · Cited by 391
Self-citation
Cited by
Sorted by citations
Items 201–208 of 208
Third Section: Design of a dimeric-nanobody specific for Aβ42 oligomers: the Dimeric-DesAb-O
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.06
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.03
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.04
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.02
Conclusion and Future Perspectives
Napolitano, L. (2026) · Firenze University Press eBooks · doi:10.36253/979-12-215-0993-9.08
Rawal, P., Moon, H.-J., Nguyen, V., Khatri, S., Larson, M. A., Vivian, J. C., Saido, T. C., & Zhao, L. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.30.741791
Aducanumab: a decade in the making and a hopeful tactic for addressing alzheimer’s
Gollapudi, R., Medabalimi, V., Nallam, S. M., Kolusu, A. S., Kalidindi, V. R., & Samudrala, P. K. (2026) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s2175-97902026e24625
Metadata
- Authors
- Selkoe, D. J.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Selkoe, Dennis J.
- ORCID
- Selkoe, Dennis J.
- Venue
- Nature Reviews Neurology
- Published
- 2019-05-28
- Volume
- 15
- Issue
- 7
- Pages
- 365-366
- ISSN
- 1759-4758 (ISSN-L)
- 1759-4766
- OpenAlex
- W2946865729
- Cited by
- 208
- References
- 5
- Citations by year
- 2026: 17 · 2025: 14 · 2024: 19 · 2023: 19 · 2022: 37 · 2021: 35 · 2020: 47 · 2019: 19
- FWCI
- 23.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Reviews Neurology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, aducanumab, anti-amyloid immunotherapy, amyloid-beta, disease-modifying therapy, phase III trial results, treatment options
- MeSH terms
- Alzheimer Disease, Clinical Trials as Topic, Humans, Amyloid beta-Peptides, Treatment Failure, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
